We demonstrated that inhibitors of HGF activation such as SRI 31215 represent a novel approach to inhibit autocrine and paracrine oncogenic HGF/MET signaling and to prevent HGF-dependent proliferation, EMT and migration of cancer cells. This evidence concerns the gene MET and cancer.